BR112017013696A2 - peptídeos e seu uso no tratamento de pele - Google Patents

peptídeos e seu uso no tratamento de pele

Info

Publication number
BR112017013696A2
BR112017013696A2 BR112017013696A BR112017013696A BR112017013696A2 BR 112017013696 A2 BR112017013696 A2 BR 112017013696A2 BR 112017013696 A BR112017013696 A BR 112017013696A BR 112017013696 A BR112017013696 A BR 112017013696A BR 112017013696 A2 BR112017013696 A2 BR 112017013696A2
Authority
BR
Brazil
Prior art keywords
peptides
skin treatment
compositions
skin
gdf11
Prior art date
Application number
BR112017013696A
Other languages
English (en)
Other versions
BR112017013696B1 (pt
Inventor
Idkowiak Baldys Jolanta
Santhanam Uma
Original Assignee
Avon Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avon Prod Inc filed Critical Avon Prod Inc
Publication of BR112017013696A2 publication Critical patent/BR112017013696A2/pt
Publication of BR112017013696B1 publication Critical patent/BR112017013696B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof

Abstract

as modalidades da invenção se referem, de modo geral, a métodos para diminuir os sinais de envelhecimento e/ou melhorar a saúde de tegumentos humanos, como pele, e composições que compreendem os peptídeos úteis para isso. as composições de acordo com a invenção podem compreender um ou mais peptídeos ou fragmentos ou derivados dos mesmos derivados de um fator de crescimento, por exemplo, fator de diferenciação de crescimento 11 (gdf11), em um veículo topicamente aceitável.
BR112017013696-1A 2014-12-23 2015-09-03 Método para diminuir o aparecimento de sinais dermatológicos do envelhecimento BR112017013696B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462095873P 2014-12-23 2014-12-23
US62/095,873 2014-12-23
PCT/US2015/048240 WO2016105607A1 (en) 2014-12-23 2015-09-03 Peptides and their use in the treatment of skin

Publications (2)

Publication Number Publication Date
BR112017013696A2 true BR112017013696A2 (pt) 2018-02-06
BR112017013696B1 BR112017013696B1 (pt) 2024-01-02

Family

ID=56128191

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017013696-1A BR112017013696B1 (pt) 2014-12-23 2015-09-03 Método para diminuir o aparecimento de sinais dermatológicos do envelhecimento

Country Status (10)

Country Link
US (1) US10034826B2 (pt)
EP (1) EP3236992A4 (pt)
CN (1) CN107106652A (pt)
BR (1) BR112017013696B1 (pt)
CA (1) CA2972015A1 (pt)
MX (1) MX2017008454A (pt)
PH (1) PH12017501070A1 (pt)
RU (1) RU2709778C2 (pt)
WO (1) WO2016105607A1 (pt)
ZA (1) ZA201704726B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101810385B1 (ko) * 2016-02-04 2017-12-20 주식회사 강스템바이오텍 Gdf11을 포함하는 조성물 및 그의 용도
US11766467B2 (en) 2017-09-01 2023-09-26 University Of Wyoming Methods of treating wounds using cathepsin K inhibitors
US10758559B1 (en) 2017-09-01 2020-09-01 University Of Wyoming Targeting cathepsin K to facilitate wound healing
CN117777238A (zh) * 2017-09-15 2024-03-29 凯恩塞恩斯株式会社 作为自身免疫疾病及骨病治疗剂的肽的用途
CN108586575B (zh) * 2018-04-11 2020-08-14 福建省中科生物股份有限公司 一种多肽及其皮肤修复功能的应用
MX2021008115A (es) 2019-01-04 2021-08-11 Avon Prod Inc Derivados oxidados de fragmentos de gdf-11.
JP2022530036A (ja) * 2019-04-24 2022-06-27 フォリクム エービー 局所製剤
US20230320967A1 (en) * 2020-09-11 2023-10-12 Chemyunion Ltda. Composition, use of the composition, cosmetic method for modulating the production of sebum

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5492894A (en) * 1991-03-21 1996-02-20 The Procter & Gamble Company Compositions for treating wrinkles comprising a peptide
US20030167492A1 (en) 1994-07-08 2003-09-04 Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
US7101664B2 (en) * 1999-12-22 2006-09-05 Polymun Scientific Immunbiologische Forschung Gmbh Bioactive oligopeptides
CA2462791A1 (en) 2001-10-05 2003-04-17 Procyte Corporation Skin care compositions containing peptide copper complexes and retinol, retinol derivatives, or a mixture thereof
JP2005533855A (ja) 2002-07-24 2005-11-10 インターツェル・アクチェンゲゼルシャフト 病原性ウイルスからの別のリーディングフレームによりコードされる抗原
WO2004043482A1 (fr) * 2002-11-08 2004-05-27 Societe D'extraction Des Principes Actifs (Vincience) Composition cosmetique ou pharmaceutique comprenant des peptides, possedant le motif arg-gly-ser
US7141544B2 (en) * 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
WO2005120554A1 (en) * 2004-06-14 2005-12-22 Cognis France S.A.S. Cosmetic preparations containing pth fragments
TWI415628B (zh) 2006-02-28 2013-11-21 Avon Prod Inc 包含具有非天然胺基酸之胜肽之組合物及其使用方法
DK2121142T3 (da) * 2007-01-25 2013-07-29 Bioph Biotech Entw Pharm Gmbh Anvendelse af GDF-5 til forbedring eller vedligeholdelse af hudens udseende
US8987212B2 (en) 2007-08-07 2015-03-24 Muhammed Majeed Oleanoyl peptide composition and method of treating skin aging
WO2009124754A1 (en) * 2008-04-08 2009-10-15 Merck Patent Gmbh Compositions containing cyclic peptides and methods of use
BR112012000865A2 (pt) 2009-07-17 2019-09-24 T Tabor Aaron "composição e método para a modificação genética cosmética de células substancialmente intactas"
WO2011063152A1 (en) * 2009-11-18 2011-05-26 Affinergy, Inc. Methods and compositions for soft tissue repair
CA2785633C (en) * 2009-12-28 2014-07-15 N.V. Perricone Llc Topical acyl glutathione formulations
CN101884602A (zh) * 2010-03-03 2010-11-17 孙杰 一种皮肤美容修复抗衰除皱的化妆品制剂
KR20130052441A (ko) * 2011-11-11 2013-05-22 (주) 코웰메디 재조합 인간 골형성 단백질과 트위스트 전사인자를 활성성분으로 함유하는 피부조직 재생용 조성물 및 키트
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
FR2998570B1 (fr) * 2012-11-26 2016-12-02 Sederma Sa Peptides, compositions les comprenant et utilisations notamment cosmetiques propigmentantes
WO2014140890A2 (en) * 2013-03-13 2014-09-18 Neocutis Sa Peptides for skin rejuvenation and methods of using the same
CA2942478A1 (en) * 2013-03-13 2014-10-02 Stemetrix, Inc. Skin compositions and uses
ITRM20130199A1 (it) 2013-04-03 2014-10-04 Irbm Science Park S P A Peptidi per uso dermatologico e/o cosmetico
EP4140497A1 (en) * 2013-04-08 2023-03-01 President and Fellows of Harvard College Compositions for rejuvenating skeletal muscle stem cells
US9125843B2 (en) * 2013-10-03 2015-09-08 Elc Management Llc Methods and compositions for improving the appearance of skin
WO2016105365A1 (en) * 2014-12-23 2016-06-30 Avon Products, Inc. Peptides and their use in the treatment of skin
WO2016105360A1 (en) * 2014-12-23 2016-06-30 Avon Products, Inc. Peptides and their use in the treatment of skin
EP3236980A1 (en) * 2014-12-23 2017-11-01 Avon Products, Inc. Peptides and their use in the treatment of skin
US9597274B2 (en) * 2015-06-17 2017-03-21 Avon Products, Inc. Peptides and their use in the treatment of skin

Also Published As

Publication number Publication date
US10034826B2 (en) 2018-07-31
RU2709778C2 (ru) 2019-12-20
PH12017501070A1 (en) 2017-12-11
CA2972015A1 (en) 2016-06-30
EP3236992A4 (en) 2018-09-05
EP3236992A1 (en) 2017-11-01
MX2017008454A (es) 2017-10-31
BR112017013696B1 (pt) 2024-01-02
RU2017123388A (ru) 2019-01-24
RU2017123388A3 (pt) 2019-01-25
CN107106652A (zh) 2017-08-29
WO2016105607A1 (en) 2016-06-30
ZA201704726B (en) 2019-01-30
US20160175225A1 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
BR112017013696A2 (pt) peptídeos e seu uso no tratamento de pele
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EP4289910A3 (en) Methods and compositions for wound healing
BR112015019440A8 (pt) curativo regulável, kit, uso e método para fortalecimento da pele
BR112018017172A2 (pt) anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
BR112017016068A2 (pt) composições para modulação de expressão de c9orf72
MX2017001281A (es) Material anisotropico biocompuesto, implantes medicos que lo comprenden y metodos para el tratamiento del mismo.
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
PH12019501199A1 (en) Calcium lactate compositions and methods of use
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
AU2017248276A1 (en) Methods of treating ocular conditions
BR112017011425A2 (pt) aumento do crescimento de planta usando guars catiônico
BR112015021483A2 (pt) arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer
BR112018003780A2 (pt) composições que compreendem um composto de urolitina
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
BR112017019971A2 (pt) exclusão de éxon induzida por anti-sentido em miostatina
BR112019017393A2 (pt) formulações de evolocumab de baixa viscosidade, alta concentração e métodos para produzir as mesmas
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
BR112017022523A2 (pt) ?formulação para cápsulas de gel, cápsula de gel, e, processo?.
BR112016016901A2 (pt) agentes para o uso no tratamento de inflamação retinal
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/09/2015, OBSERVADAS AS CONDICOES LEGAIS